Canopy Growth (CGC) Liabilities and Shareholders Equity (2017 - 2026)

Canopy Growth (CGC) reported Liabilities and Shareholders Equity of $815.8 million for Q1 2026, up 27.55% on a YoY basis from $639.6 million in Q1 2025, and up 2.84% sequentially from $793.2 million in Q4 2025.

Canopy Growth (CGC) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends

Canopy Growth (CGC) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $815.8 million in Q1 2026.

  • For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 27.55% year-over-year to $815.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 billion (down 8.36% YoY), and the FY2026 full-year result was $815.8 million, up 27.55% from the prior year.
  • Liabilities and Shareholders Equity rose to $815.8 million in Q1 2026, from $793.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $4.4 billion in Q1 2022 to a low of $639.6 million in Q1 2025.
  • A 5-year average of $1.5 billion and a median of $965.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • Across the five-year window, Liabilities and Shareholders Equity sank 59.22% in 2023 and rose 27.55% in 2026, its largest moves.
  • Tracing CGC's Liabilities and Shareholders Equity over 5 years: stood at $2.2 billion in 2022, then plunged by 53.88% to $998.8 million in 2023, then declined by 16.56% to $833.4 million in 2024, then dropped by 4.82% to $793.2 million in 2025, then rose by 2.84% to $815.8 million in 2026.
  • Business Quant data shows CGC's Liabilities and Shareholders Equity at $815.8 million in Q1 2026, $793.2 million in Q4 2025, and $777.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 43.40 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 40.04 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 15.15 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 98.91 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 6.71 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 69.30 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 36.83 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 4.91 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 13.22 Bn
10 Canopy Growth 197.77 Mn -68.15 Mn - 815.79 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 815.79 Mn
Dec 31, 2025 793.24 Mn
Sep 30, 2025 777.38 Mn
Jun 30, 2025 652.91 Mn
Mar 31, 2025 639.56 Mn
Dec 31, 2024 833.41 Mn
Sep 30, 2024 903.38 Mn
Jun 30, 2024 940.41 Mn
Mar 31, 2024 964.99 Mn
Dec 31, 2023 998.79 Mn
Sep 30, 2023 1.24 Bn
Jun 30, 2023 1.63 Bn
Mar 31, 2023 1.80 Bn
Dec 31, 2022 2.17 Bn
Sep 30, 2022 2.55 Bn
Jun 30, 2022 2.75 Bn
Mar 31, 2022 4.43 Bn
Dec 31, 2021 5.01 Bn
Sep 30, 2021 5.16 Bn
Jun 30, 2021 5.67 Bn